Bio-Path Holdings Inc (NASDAQ:BPTH) has been given a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.

Brokerages have set a 1-year consensus price target of $28.00 for the company and are predicting that the company will post ($0.60) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Bio-Path an industry rank of 87 out of 256 based on the ratings given to related companies.

Separately, HC Wainwright restated a “buy” rating on shares of NioCorp Developments in a research note on Tuesday, July 16th.

An institutional investor recently bought a new position in Bio-Path stock. Virtu Financial LLC acquired a new stake in shares of Bio-Path Holdings Inc (NASDAQ:BPTH) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 16,461 shares of the company’s stock, valued at approximately $336,000. Virtu Financial LLC owned approximately 0.66% of Bio-Path at the end of the most recent reporting period. 10.77% of the stock is owned by institutional investors.

Shares of Bio-Path stock traded up $0.13 on Wednesday, hitting $13.85. The stock had a trading volume of 900 shares, compared to its average volume of 282,221. Bio-Path has a one year low of $1.61 and a one year high of $73.52. The firm has a market cap of $39.42 million, a PE ratio of -0.97 and a beta of 3.25. The firm has a 50-day moving average of $13.54.

Bio-Path (NASDAQ:BPTH) last posted its quarterly earnings results on Thursday, May 16th. The company reported ($0.89) earnings per share (EPS) for the quarter. As a group, analysts expect that Bio-Path will post -3.08 EPS for the current fiscal year.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.

See Also: How Do Mutual Funds Work?

Get a free copy of the Zacks research report on Bio-Path (BPTH)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with's FREE daily email newsletter.